Alzheimer's Disease Clinical Trials in Orlando, Florida

6 studies are recruiting for alzheimer's disease in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 2634, Orlando, Florida

   Locations

   143 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011745 on ClinicalTrials.gov

2. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

   VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

   Stage

   Phase 1

   Ages

   30 to 80

   Site

   AdventHealth Orlando, Orlando, Florida

   Locations

   2 in total

   Run by

   Voyager Therapeutics

   See if you can join NCT07764146 on ClinicalTrials.gov

3. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

   This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive …

   Stage

   Phase 2

   Ages

   55 to 85

   Site

   K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008, Orlando, Florida

   Locations

   20 in total

   Run by

   Sanofi

   See if you can join NCT07688213 on ClinicalTrials.gov

4. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

   This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

   Stage

   Phase 3

   Ages

   55 to 80

   Site

   Charter Research - Winter Park/Orlando, Orlando, Florida

   Locations

   34 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07717411 on ClinicalTrials.gov

5. A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

   The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

   Stage

   Phase 1

   Ages

   35 to 85

   Site

   Charter Research, LLC, Orlando, Florida

   Locations

   26 in total

   Run by

   AC Immune SA

   See if you can join NCT05462106 on ClinicalTrials.gov

6. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

   Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful rel…

   Stage

   Not phased

   Ages

   60 to 90

   Site

   Charter Research, Orlando, Florida

   Locations

   26 in total

   Run by

   GAP Innovations, PBC

   See if you can join NCT06584357 on ClinicalTrials.gov